echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Lancet: Clinical trials have shown that Lopinave-Litonave is not effective in treating new crown patients.

    Lancet: Clinical trials have shown that Lopinave-Litonave is not effective in treating new crown patients.

    • Last Update: 2020-10-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Based on the results of a new randomized controlled clinical trial, researchers from the RECOVERY Collaborative Group found that the drug combination lopinavir-ritonavir did not treat COVID-19 hospitalized patients well.
    results were published online October 5, 2020 in the journal Lancet under the title "Lopinavir-ritonavir in Patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial".
    effects of 28-day mortality from the treatment of loropire-litonave.
    photo from Lancet, 2020, doi:10.1016/S0140-6736 (20) 32013-4.
    many clinical care guidelines recommend Lopinavi-Litonavi--- an antiviral drug approved for the treatment of HIV/AIDS--- for the treatment of COVID-19 inpatients.
    , however, the authors say the guidelines should now be updated.
    trial of RECOVERY (Randomized Evaluation of COVid-19 thERapY) in 176 UK hospitals is the first large-scale randomized clinical trial to report the effects of Lopinavi-Litonavi on COVID-19 inpatients.
    Landray, a professor in the Department of Population Health at Nuffield, University of Oxford, UK, who co-led the RECOVERY clinical trial, said: "The treatment of COVID-19 with the drug combination Lopinavir-Litonavi is recommended in many countries.
    , however, the results of this clinical trial show that this is not an effective treatment for patients admitted to COVID-19.
    Since our preliminary results were made public on June 29, 2020, the World Health Organization (WHO) has discontinued the Lopinave-Litonave treatment group involved in its SOLIDARITY clinical trial and reported that their interim results are consistent with our clinical trial results.
    " Between March 19 and June 29, 2020, 1,616 patients in recovery clinical trials were treated randomly with Lopinave-Litonave, while 3,424 patients received only routine care.
    those who took Lopinave-Litonave were given oral 400mg of Lopinave and 100mg of Litonave every 12 hours for 10 days, or earlier, until they were discharged from the hospital.
    end of the year was 28 days of all-cause mortality.
    trial results showed that treating COVID-19 hospitalized patients with Lopinavi-Litonavi did not reduce deaths within 28 days of the start of treatment.
    23% (374/1616 patients) of patients treated with Lopinave-Litonave and 22% (767/3424 patients) of patients receiving routine care died within 28 days.
    results of the RECOVERY clinical trial are clear," said Peter Horby, co-lead researcher on the RECOVERY clinical trial and professor in the Nafield Department of Medicine at Oxford University.
    When combined with earlier, smaller clinical trial results and WHO interim results, this provides strong evidence that Lopinavi-Litonavi is not an effective treatment for hospitalized COVID-19 patients.
    Disappointingly, Lopinave-Litonave does not have significant benefits for inpatients, but these findings allow us to focus on other promising treatments and provide an example of how individual patients are treated.
    the authors also found that Lopinave-Litonave did not shorten the length of hospital stays: in the Lopinave-Litonave group, 69 percent (1113/1616 patients) left the hospital within 28 days, while 70 percent (2382/3424 patients) left the hospital within 28 days.
    11 days of hospitalization for both groups of patients.
    No significant differences were observed in the risk of needing a ventilator, with 10 percent (152/1556 patients) in the Lopinave-Litonave group needing to be ventilatored, while 9 percent (279/3,280 patients) in routine care needed ventilation.
    results were consistent across all patient subgroups, including age, gender and race: there was no evidence that the treatment of lopinave-litonave had any benefit.
    The authors note that because of the difficulty of treating patients who cannot swallow, few patients who have received intring therapy (inserting tubes into the air, using a ventilator to assist in breathing) participate in this clinical trial and therefore cannot draw conclusions about the effectiveness of Lopinave-Litonave in treating patients receiving mechanical aeration.
    The results of this large-scale RECOVERY clinical trial --- combined with the results of an earlier, smaller clinical trial and the interim results of the WHO--- provide strong evidence that Lopinavi-Litonavi is not an effective treatment for COVID-19 hospitalized patients and should be updated accordingly.
    a commentary on the RECOVERY clinical trial, Bin Cao of Capital Medical University and Frederick G Hayden of the University of Virginia School of Medicine, who were not involved in the clinical study, wrote, "With Cao and his colleagues at COVID-19, The first randomized clinical trial in patients to study Lopinave-Litonave provided a more solid evidence base for the possible effects of Lopinave-Litonave than in the RECOVERY clinical trial. The results of these two open-label studies support each other and conclude that Lopinavi-Litonavi is not effective in improving the treatment effectiveness of COVID-19 patients admitted to the hospital.
    " Reference: 1. RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): aized, controlled, open-label, platform trial. Lancet, 2020, doi:10.1016/S0140-6736 (20)32013-4.2.Bin et Cao al. Antiviral monotherapy for hospitalised patients with COVID-19 is not enough. Lancet, 2020, doi:10.1016/S0140-6736 (20) 32078-X.3.The Lancet: Lopinavir-ritonavir is not-an-effective treatment for patients hospitaled with COVID-19 From Bio Valley, for more information please download Bio Valley APP (
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.